Literature DB >> 46445

Insulin responses to oral carbohydrate in true prediabetics and matched controls.

P J Savage, P Gorden, P H Bennett, M Miller.   

Abstract

The definition of prediabetes by genetic criteria alone has limitations since not all such subjects progress to overt diabetes. Sequential oral glucose tolerance testing in a population has enabled the identification of 14 "true prediabetic" subjects with baseline two-hour plasma glucose levels smaller than 160 mg. per 100 ml. who subsequently developed unequivocal diabetes (two-hour plasma glucose level larger than 275 mg. per 100 ml.). All but one were matched for baseline two-hour plasma glucose and relative weight with a subject whose glucose tolerance remained unchanged during a mean follow-up period of 4 years. Fasting insulin levels and responses at 1/2, 1, and 2 hour sampling times were similar in both group and matched pair analysis at baseline. No evidence was found that subjects destined to develop diabetes have either excessive or diminished insulin secretion.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 46445     DOI: 10.1016/s0140-6736(75)91207-6

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  3 in total

1.  Metabolic abnormalities in children of non-insulin dependent diabetics.

Authors:  R D Leslie; H P Volkmann; M Poncher; I Hanning; H Orskov; K G Alberti
Journal:  Br Med J (Clin Res Ed)       Date:  1986-10-04

2.  Risk factors for worsening to diabetes in subjects with impaired glucose tolerance.

Authors:  T Kadowaki; Y Miyake; R Hagura; Y Akanuma; H Kajinuma; N Kuzuya; F Takaku; K Kosaka
Journal:  Diabetologia       Date:  1984-01       Impact factor: 10.122

3.  Effects of chronic metformin treatment on training adaptations in men and women with hyperglycemia: A prospective study.

Authors:  Alfonso Moreno-Cabañas; Felix Morales-Palomo; Laura Alvarez-Jimenez; Juan Fernando Ortega; Ricardo Mora-Rodriguez
Journal:  Obesity (Silver Spring)       Date:  2022-05-17       Impact factor: 9.298

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.